Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload.

Authors: Brancaccio, M  Fratta, L  Notte, A  Hirsch, E  Poulet, R  Guazzone, S  De Acetis, M  Vecchione, C  Marino, G  Altruda, F  Silengo, L  Tarone, G  Lembo, G 
Citation: Brancaccio M, etal., Nat Med. 2003 Jan;9(1):68-75. Epub 2002 Dec 23.
Pubmed: (View Article at PubMed) PMID:12496958
DOI: Full-text: DOI:10.1038/nm805

Cardiac hypertrophy is an adaptive response to a variety of mechanical and hormonal stimuli, and represents an early event in the clinical course leading to heart failure. By gene inactivation, we demonstrate here a crucial role of melusin, a muscle-specific protein that interacts with the integrin beta1 cytoplasmic domain, in the hypertrophic response to mechanical overload. Melusin-null mice showed normal cardiac structure and function in physiological conditions, but when subjected to pressure overload--a condition that induces a hypertrophic response in wild-type controls--they developed an abnormal cardiac remodeling that evolved into dilated cardiomyopathy and contractile dysfunction. In contrast, the hypertrophic response was identical in wild-type and melusin-null mice after chronic administration of angiotensin II or phenylephrine at doses that do not increase blood pressure--that is, in the absence of cardiac biomechanical stress. Analysis of intracellular signaling events induced by pressure overload indicated that phosphorylation of glycogen synthase kinase-3beta (GSK-3beta) was specifically blunted in melusin-null hearts. Thus, melusin prevents cardiac dilation during chronic pressure overload by specifically sensing mechanical stress.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 1582491
Created: 2006-11-10
Species: All species
Last Modified: 2006-11-10
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.